|
Sep 03, 2024
|
Nkarta to Participate in Upcoming Investor Conference
|
|
|
Aug 13, 2024
|
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
|
|
Jul 24, 2024
|
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
|
|
|
Jul 16, 2024
|
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
|
|
|
Jun 27, 2024
|
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
|
|
|
Jun 13, 2024
|
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
|
|
|
May 09, 2024
|
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
|
|
|
Apr 03, 2024
|
Nkarta to Participate in Upcoming Investor Conferences
|
|
|
Mar 25, 2024
|
Nkarta Announces Pricing of $240 Million Underwritten Offering
|
|
|
Mar 21, 2024
|
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
|
|
